When confronted with advanced cancer

Select Appropriate Therapy

CellDxis a comprehensive test to analyse actionable therapy options using guideline recommended genes in solid tumors.

What is Deep Genomic Analysis ?

Deep genomic analysis is a method of detecting the four main classes of modifications known to drive cancer growth: base substitutions, insertions and deletions, copy number alterations (CNAs), and fusions. This test can be done on FFPE tissue, peripheral whole blood, bone marrow aspirate, or extracted nucleic acid, among other specimen types. When compared to traditional molecular testing, deep genomic analysis helps you better anticipate response or resistance to targeted and immunotherapies for more advanced cancer patients.

The Advantage of CellDx

Based on the particular genomic profile of each patient’s cancer, CellDx is designed to offer physicians with clinically meaningful information — both to select appropriate therapy for patients and to comprehend results with evidence of resistance.

When

Should I Consider CellDx

Diagnosed with cancer and advised molecular profiling of the tumor to explore targeted therapies / immunotherapies.

Features

  • Targeted Therapy : Evaluation of companion diagnostic therapies across several cancer indications, and clinical trial matching across all solid tumors.
  • Immunotherapy : Helps inform immunotherapy decisions by including genomic signatures such as Microsatellite Instability (MSI), Tumor Mutational Burden (TMB) and PD-L1 status.
  • Simplified Report : All results are provided in a simplified report, with indications for approved therapies and genomic highlights.
  • 511 Genes (SNVs, CNAs, Fusions and Indels).

Features

  • Targeted Therapy : Evaluation of companion diagnostic therapies across several cancer indications, and clinical trial matching across all solid tumors.
  • Immunotherapy : Helps inform immunotherapy decisions by including genomic signatures such as microsatellite instability (MSI), tumor mutational burden (TMB) and PDL1 status.
  • Simplified Report : All results are provided in a simplified report, with indications for approved therapies and genomic highlights.
  • 452 Genes (SNVs, CNAs, Fusions and Indels).

Biomarker-based Drug Indications

Biomarker US FDA - Approved Therapy
EGFR exon 19 deletions / exon 21 L858R
Gefitinib, Erlotinib, Afatinib, Dacomitinib, Osimertinib
EGFR exon 20 insertion mutation
Amivantamab
EGFR T790M
Osimertinib
KRAS G12C
Sotorasib
ALK rearrangements
Alectinib, Crizotinib, Ceritinib, Lorlatinib, Brigatinib
BRAF V600E
Dabrafenib in comibation with Trametinib
ROS1 rearrangements
Entrectinib, Crizotinib
RET rearrangements
Selpercatinib, Pralsetinib
MET exon 14 skipping mutation
Capmatinib, Tepotinib
NTRK fusions
Larotrectinib, Entrectinib
PDL1
Pembrolizumab, Nivolumab, Atezolizumab

Biomarker US FDA - Approved Therapy
KRAS wild-type
Cetuximab, Panitumumab
MSI-H/dMMR
Nivolumab + Ipilimumab or Pembrolizumab

Biomarker US FDA - Approved Therapy
ERBB2 (HER2) amplification
Lapatinib, Neratinib, Trastuzumab, Ado-trastuzumab emtansine, Pertuzumab, Margetuximab, Tucatinib, Fam-trastuzumab deruxtecan
PDL1 (SP142)
Atezolizumab
BRCA1/2 alterations
Olaparib, Talazoparib
PIK3CA
Alpelisib

Biomarker US FDA - Approved Therapy
BRCA1/2 alterations
Olaparib, Rucaparib, Niraparib
HRD deficient tumors
Niraparib

Biomarker US FDA - Approved Therapy
BRAF V600E
Dabrafenib or Vemurafenib
BRAF V600E or V600K
Trametinib or Cobimetinib in combination with Dabrafenib or Vemurafenib

Biomarker US FDA - Approved Therapy
NTRK
Entrectinib, Larotrectinib
MSI-H/dMMR
Pembrolizumab

Biomarker US FDA - Approved Therapy
FGFR2, FGFR3 gene alterations
Erdafitinib
PDL1
Pembrolizumab, Atezolizumab

Biomarker US FDA - Approved Therapy
ERBB2 (HER2) overexpression
Trastuzumab, Fam-Trastuzumab deruxtecan

Biomarker US FDA - Approved Therapy
FGFR2 (fusion / rearrangement)
Infigratinib, Pemigatinib

Biomarker US FDA - Approved Therapy
BRCA1/2 mutation
Olaparib

Biomarker US FDA - Approved Therapy
HRR deficient tumors, BRCA1/2 mutations
Olaparib

Want to delve a little deeper?

If you have questions or would like to know more about test performance, download the brochure.

We’re here to assist you

If you have any questions or want to learn more, please contact us or visit our FAQs.